KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $1.3 billion.

  • Pacira BioSciences' Liabilities and Shareholders Equity fell 14.73% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year decrease of 5.55%. This contributed to the annual value of $1.6 billion for FY2024, which is 1.33% down from last year.
  • Per Pacira BioSciences' latest filing, its Liabilities and Shareholders Equity stood at $1.3 billion for Q3 2025, which was down 15.59% from $1.5 billion recorded in Q2 2025.
  • Pacira BioSciences' 5-year Liabilities and Shareholders Equity high stood at $2.1 billion for Q4 2021, and its period low was $1.3 billion during Q1 2021.
  • Over the past 3 years, Pacira BioSciences' median Liabilities and Shareholders Equity value was $1.5 billion (recorded in 2023), while the average stood at $1.5 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 62.83% in 2021, then dropped by 19.46% in 2023.
  • Pacira BioSciences' Liabilities and Shareholders Equity (MRQ) stood at $2.1 billion in 2021, then fell by 18.99% to $1.7 billion in 2022, then fell by 6.35% to $1.6 billion in 2023, then fell by 1.33% to $1.6 billion in 2024, then fell by 16.47% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.6 billion during Q1 2025.